Recordati Industria Chimica e Farmaceutica Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Rob Koremans
Chief executive officer
€2.5m
Total compensation
| CEO salary percentage | 23.6% |
| CEO tenure | 3.1yrs |
| CEO ownership | n/a |
| Management average tenure | 4.4yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jan 05
Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?
Dec 18We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings
Nov 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60
Nov 14Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 13Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar
Oct 31Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 07We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | €423m |
| Jun 30 2024 | n/a | n/a | €387m |
| Mar 31 2024 | n/a | n/a | €389m |
| Dec 31 2023 | €2m | €590k | €389m |
| Sep 30 2023 | n/a | n/a | €375m |
| Jun 30 2023 | n/a | n/a | €389m |
| Mar 31 2023 | n/a | n/a | €340m |
| Dec 31 2022 | €2m | €590k | €312m |
| Sep 30 2022 | n/a | n/a | €331m |
| Jun 30 2022 | n/a | n/a | €330m |
| Mar 31 2022 | n/a | n/a | €393m |
| Dec 31 2021 | €154k | n/a | €386m |
Compensation vs Market: Rob's total compensation ($USD2.57M) is about average for companies of similar size in the Italian market ($USD2.65M).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Koremans (62 yo)
3.1yrs
Tenure
€2,498,000
Compensation
Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | €2.50m | no data | |
| Group CFO & Executive Director | 5.2yrs | €1.23m | no data | |
| Executive Director | no data | no data | no data | |
| Executive Director | 6yrs | no data | no data | |
| Executive Director | 4.8yrs | no data | no data | |
| VP & Head of Investor Relations | less than a year | no data | no data | |
| Group Chief Legal Officer | 1.8yrs | no data | no data | |
| Group Communications Director | no data | no data | no data | |
| Executive VP of Corporate Development | 8.3yrs | no data | no data | |
| Group Chief People & Culture Officer | less than a year | no data | no data | |
| Chief Medical Officer | 6yrs | no data | no data | |
| Executive Vice President of Specialty & Primary Care Business Unit | 4yrs | no data | no data |
4.4yrs
Average Tenure
55yo
Average Age
Experienced Management: REC's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | €2.50m | no data | |
| Group CFO & Executive Director | 3yrs | €1.23m | no data | |
| Executive Director | 6.1yrs | no data | no data | |
| Executive Director | 6.1yrs | no data | no data | |
| Executive Director | 4.8yrs | no data | no data | |
| Non-Executive Chairman | 26.8yrs | €315.00k | no data | |
| Independent Non-Executive Director | 4.8yrs | €80.00k | no data | |
| Lead Independent Director | 10.8yrs | €103.00k | no data | |
| Independent Director | 3yrs | €90.00k | no data | |
| Chairman of Statutory Auditor Board | 7.8yrs | no data | no data | |
| Independent Non-Executive Director | 5.9yrs | €85.00k | no data | |
| Non-Executive Vice Chairman | 4.8yrs | €90.00k | no data |
5.3yrs
Average Tenure
54.5yo
Average Age
Experienced Board: REC's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 14:37 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Charles Pitman-King | Barclays |
| Vincent Meunier | BNP Paribas Exane |